StockData
Rallybio Corp logo

Rallybio Corp (RLYB) stock

RLYBNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 27, 2026Score 10/30
$15.26−0.03 (-0.20%)

Close on Nov 18, 2026Market cap $82.16MP/E 3.3Yield –

Rallybio revenue

Revenue is the money a company takes in from selling its products and services, before any costs are deducted.

Rallybio's revenue for the twelve months ending Sep 30, 2026 was $434.00K, down 35.6% year over year. For fiscal 2025 it was $858.00K, up 34.9% from the year before.

Annual revenue

PeriodPeriod endValueChange
FY2025Dec 31, 2025$858.00K+34.9%
FY2024Dec 31, 2024$636.00K–

Quarterly revenue

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q3 FY2026Sep 30, 2026$0-100.0%
Q2 FY2026Jun 30, 2026$0-100.0%
Q1 FY2026Mar 31, 2026$212.00K0.0%
Q4 FY2025Dec 31, 2025$222.00K+484.2%
Q3 FY2025Sep 30, 2025$212.00K-29.1%
Q2 FY2025Jun 30, 2025$212.00K-29.1%
Q1 FY2025Mar 31, 2025$212.00K–
Q4 FY2024Dec 31, 2024$38.00K–
Q3 FY2024Sep 30, 2024$299.00K–
Q2 FY2024Jun 30, 2024$299.00K–
Q1 FY2024Mar 31, 2024$0–
Q3 FY2023Sep 30, 2023$0–
Q2 FY2023Jun 30, 2023$0–

More Rallybio figures

See a number that looks wrong?